(P 298) PROGNOSIS OF PATIENTS WITH CUTANEOUS ANGIOSARCOMA AFTER SURGICAL RESECTION WITH CURATIVE INTENT: IS THERE A DIFFERENCE BETWEEN THE SUBTYPES?

Author(s)

Sophie JM Reijers, MD (she/her/hers)

PhD candidate
Nederlands Cancer Institute
Amsterdam, Noord-Holland, Netherlands

Co-Author(s)

EH

Eva Huis in 't Veld, MD

Erasmus Medical Center
Rotterdam, Zuid-Holland, Netherlands
DG

Dirk J. Grünhagen, N/A, MD, PhD

Associate Professor Surgical Oncology
Erasmus Medical Center
Rotterdam, Zuid-Holland, Netherlands
Myles JF Smith, MB BCh BAO, PhD, FRCSI, FRCS

Surgical Oncologist
Sarcoma Unit, Royal Marsden Hospital
London, England, United Kingdom
Tessa van Ginhoven, MD PhD

Surgical Oncologist
Erasmus Medical Center
Rotterdam, Zuid-Holland, Netherlands
Frits van Coevorden, MD, PhD (he/him/his)

Retired
The Netherlands Cancer Institute
Amstelveen, Noord-Holland, Netherlands
Winette T.A van der Graaf, MD, PhD

Professor of Medical Oncology at NKI and ErasmusMC; Head of Department of Medical Oncology at NKI; Groupleader AYA and Sarcoma Research at NKI
Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands
Amsterdam, Noord-Holland, Netherlands
YS

Yvonne M. Schrage, N/A, MD PhD

Netherland Cancer Institute
Amsterdam, Noord-Holland, Netherlands
Dirk Strauss, MMed, FCS, FRCS

Surgical Oncologist
Sarcoma Unit, The Royal Marsden Hospital NHS Foundation Trust
London, England, United Kingdom
CV

Cornelis Verhoef, N/A, MSc, MD, PhD

Professor of Surgery
Erasmus Medical Center
Rotterdam, Zuid-Holland, Netherlands
Andrew J. Hayes, MD PhD

Consultant Surgical Oncologist
Royal Marsden Hospital
London, England, United Kingdom
Winan J. Van Houdt, MSc, MD, PhD

Surgical Oncologist
The Netherlands Cancer Institute
Amsterdam, Noord-Holland, Netherlands

Objective: The etiology of cutaneous angiosarcoma (cAS) may be idiopathic (I-cAS), or arise secondary to radiotherapy (RT-cAS), in chronic lymphedema (ST-cAS) or related to UV exposure (UV-cAS). The aim of this study was to evaluate oncological outcomes of different cAS subtypes.

Methods: Non-metastatic cAS patients, treated with surgery for primary disease with curative intent were retrospectively analyzed for oncological outcome, including local recurrence (LR), distant metastases (DM) and overall survival (OS).

Results: A total of 234 patients were identified; 60 I-cAS, 122 RT-cAS, 9 ST-cAS and 43 UV-cAS. The majority was female (78%), the median age was 66 years (IQR 57-76), the median tumor size was 4.4 cm (IQR 2.5-7.0) and most common site of disease was the breast (59%). Recurrence was identified in 66% (44% LR and/or 41% DM), with a median follow up of 26.5 months (IQR 12-60). The 5-year OS was estimated at 50%, LRFS at 47% and DMFS at 50%. There was no significant difference in LR, DM and OS between the subtypes. Age < 65 years and administration of radiotherapy (RT) were significantly associated with lower LR rates (respectively HR 0.560, 95% CI 0.3373-0.840, p=0.005 and HR 0.421, 95% CI 0.225-0.790, p=0.007), however no prognostic factors were identified for development of DM. Development of DM, but not LR, was significantly associated with decreased OS (HR 6.486, 95% CI 2.939-14.318 p< 0.001).

Conclusion: We found no significant difference in oncological outcome between the different cAS subtypes. OS remains relatively poor, and RT is associated with lower LR rates.